PureHoney Technologies is a contract research organization that helps pharmaceutical and biotech discovery teams accelerate drug discovery research by enabling intractable targets. Founded by the original developers of the RapidFire MS instrumentation, PureHoney Tech uses the high-throughput mass spectrometry platform to perform analyses of challenging analytes across a broad range of therapeutic areas.
PureHoney Tech applies mass spectrometry-based screening to a wide range of targets, including those with substrates such as lipids, fatty acids, phospholipids, steroids, prostaglandins, and other compounds not generally amenable to conventional screening techniques. They offer a broad range of early stage services including: enzymology and characterization of targets, custom HTS assay development, hit identification, fragment-based screening, hit validation, SAR screening and in vitro ADME sample screening.
PureHoney Technologies headquarters and screening laboratories are located in Acton, Massachusetts.
Simply send us your quenched assay plates and we’ll do the rest. We can help develop new assays or use your existing assay to screen your compound libraries quickly, efficiently and inexpensively. The expert scientists at PureHoney Tech will provide you with high-quality, label-free data in a fraction of the time required for most other label-free technologies, getting your project moving through the drug discovery pipeline.
Method development services for biochemical assays and mass spectrometric analysis.
Our scientists have analyzed millions of wells spanning a variety of challenging targets across a broad array of therapeutic areas. We are specialists in label free assay development and screening using native substrates on mass spectrometers. With more than 30 years combined experience, we can help get your investigations done fast and rich with accurate data.
You receive personalized attention and counsel working directly with one of our Ph.D.’s to develop a customized assay solution for your specified target. Mass spectrometry-based screening can be applied to a wide range of targets, including those intractable targets with substrates such as lipids, fatty acids, phospholipids, steroids, prostaglandins, and other compounds not generally amenable to conventional screening techniques.
Our drug discovery research services are conducted using the Agilent RapidFire platform. The ability of mass spectrometry to selectively and accurately quantify native analytes directly, without the requirement of antibodies or optically active labels, allows PureHoney Tech to develop new assays for the most challenging of targets. The throughput and capacity of the RapidFire system enables our scientists to provide you dependable mass spectrometry based data with unparalleled turnaround times.
Business Development, Marketing & Operations Services
Business Operations and Logistics Support Services
ADME/DMPK Studies Services
PureHoney Technologies has not received any reviews.
PureHoney Technologies has not received any endorsements.